|  |
FDA Panel: Keep COX-2 Drugs on Market
Nieuws van: JAMA
Black Box for COX-2 Labels, Caution Urged for All NSAIDs
Bridget M. Kuehn
JAMA. 2005;293:1571-1572.
With questions remaining about the safety of nonsteroidal anti-inflammatory drugs (NSAIDs), a Food and Drug Administration (FDA) advisory panel recommended that the agency allow the marketing of NSAIDs that selectively inhibit cyclooxygenase 2 (COX-2) but urged greater caution with the use of all NSAIDs. At press time, the FDA had yet to make a decision about the recommendations.
Far from providing the clear-cut answers many had hoped for, the panel’s analysis of clinical data painted a nuanced picture of the risks and benefits of NSAIDs. The panel found important differences between rofecoxib, celecoxib, and valdecoxib—the three COX-2 inhibitors at the center of the debate over NSAID safety, but also noted that all three pose serious risks.
http://jama.ama-assn.org/cgi/content/extract/293/13/1571 - 7 Apr 2005
|
|
|
|
Printen
Doorsturen